Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT06420388 |
Other study ID # |
EMRP28112N |
Secondary ID |
|
Status |
Recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
May 1, 2023 |
Est. completion date |
October 1, 2024 |
Study information
Verified date |
May 2024 |
Source |
E-DA Hospital |
Contact |
Chen Chih-i |
Phone |
+886978060015 |
Email |
ed111988[@]edah.org.tw |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The study is a randomized, double-blind, controlled trial evaluating the efficacy of 2%
lidocaine gel in reducing postoperative pain and analgesic consumption after
haemorrhoidectomy. 222 patients undergoing Ferguson haemorrhoidectomy will be randomly
assigned to receive either 2% lidocaine gel or a non-anaesthetic lubricant gel control. Pain
scores using a visual analog scale (VAS) will be assessed at 12 and 24 hours, and 2, 3, and 7
days postoperatively. Analgesic consumption will also be measured.
Description:
Title: Efficacy of 2% Lidocaine Gel in Reducing Postoperative Pain and Analgesic Consumption
Following Haemorrhoidectomy: A Randomized, Double-Blind, Controlled Trial Objective: To
assess the effect of 2% lidocaine gel on postoperative pain intensity and analgesic
consumption following haemorrhoidectomy.
Study Design: This study is a single-center, randomized, double-blind, controlled trial.
Patients will be randomly assigned in a 1:1 ratio to receive either 2% lidocaine gel or a
non-anaesthetic water-based lubricant gel (control) using a computer-generated randomization
list. The randomization will be stratified by hemorrhoid grade (III or IV). The study
medication will be prepared by the hospital pharmacy and provided in identical, pre-filled
syringes to ensure blinding of participants and investigators.
Intervention: The intervention group will receive 5 mL of 2% lidocaine gel, while the control
group will receive 5 mL of a non-anaesthetic water-based lubricant gel. The study medication
will be applied to the perianal region three times per day for 7 days following surgery.
Patients will be instructed on the proper application technique and will be provided with a
diary to record the time and date of each application.
Outcome Assessment: Postoperative pain will be assessed using a 100 mm visual analog scale
(VAS), with 0 representing no pain and 100 representing the worst imaginable pain. Pain
scores will be recorded at 12 and 24 hours, and 2, 3, and 7 days after surgery. Patients will
also record their analgesic consumption in a diary, including the type, dose, and frequency
of analgesics used. Postoperative complications, such as bleeding, infection, or urinary
retention, will be assessed by the treating surgeon at each follow-up visit.
Sample Size: A sample size of 222 patients (111 per group) was calculated based on a power of
80%, a significance level of 0.05, and an expected difference in mean VAS scores of 15 mm
between the groups, with a standard deviation of 30 mm.